

REGENXBIO INC. and THE TRUSTEES
OF THE UNIVERSITY OF
PENNSYLVANIA.

 \mathbf{V}_i

SAREPTA THERAPEUTICS, INC. and
SAREPTA THERAPEUTICS THREE,
LLC.

C.A. No. 20-1226 (RGA)

JURY TRIAL DEMANDED

REDACTED – PUBLIC VERSION

Original filing date: June 8, 2023

Redacted filing date: June 15, 2023

DECLARATION OF IAN M. ESTEPAN

I, Ian M. Estepan, declare as follows:

1. I am an Executive Vice President and the Chief Financial Officer of Sarepta Therapeutics, Inc. In that capacity, I am fully familiar with the facts below. If asked to do so, I could and would testify competently thereto.

2. I submit this declaration in support of Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC's (collectively "Sarepta") Motion to Redact the transcript of the May 2, 2023 Discovery Dispute Conference (D.I. 170).

3. Sarepta seeks to redact limited, specific information from the May 2, 2023 conference transcript. For example, the highlighted portions on pages 4 and 5 of Exhibit A to the Motion discuss certain Sarepta confidential information concerning [REDACTED]

[REDACTED] a product for which a Biologics License Application (“BLA”) is currently being considered by the Food and Drug Administration (“FDA”). Sarepta maintains information concerning [REDACTED] in confidence.

HIGHLY CONFIDENTIAL – OUTSIDE COUNSEL’S EYES ONLY

4. Sarepta also seeks to redact specific numeric values and numeric ranges from pages 27 and 28 of the transcript, as well as from the word index. Those values concern plaintiffs’ [REDACTED] to Sarepta of a 35 month market delay, a value that plaintiffs derived using Sarepta’s highly-confidential, [REDACTED]

5. Sarepta maintains the information described in paragraphs 3 and 4 as confidential in the normal course of its business. Considering the cutting edge and highly competitive nature of gene therapy development, details concerning [REDACTED] are commercially sensitive, and disclosure of that information to competitors could provide competitors with an advantage that would cause Sarepta direct, competitive harm. Likewise, Sarepta’s [REDACTED] are highly sensitive, commercial information, the disclosure of which could cause Sarepta financial and business damage. Sarepta has a legitimate business interest in protecting this information from disclosure, which warrants redaction of the specific, limited information highlighted in Exhibit A.

6. I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

DATED: June 8, 2023

DocuSigned by:

Ian Estepan

CP001FC33302480
Ian M. Estepan

CERTIFICATE OF SERVICE

I hereby certify that on June 8, 2023, I caused the foregoing to be electronically filed with the Clerk of the Court using CM/ECF, which will send notification of such filing to all registered participants.

I further certify that I caused copies of the foregoing document to be served on June 8, 2023, upon the following in the manner indicated:

Susan E. Morrison, Esquire
Casey M. Kraning, Esquire
FISH & RICHARDSON P.C.
222 Delaware Avenue 17th Floor
Wilmington, DE 19801
Attorneys for Plaintiff REGENXBIO Inc.

VIA ELECTRONIC MAIL

Brian D. Coggio, Esquire
Jeremy T. Saks, Esquire
FISH & RICHARDSON P.C.
7 Times Square 20th Floor
New York, NY 10036
Attorneys for Plaintiff REGENXBIO Inc.

VIA ELECTRONIC MAIL

Kurt L. Glitzenstein, Esquire
J. Peter Fasse, Esquire
FISH & RICHARDSON P.C.
1 Marina Park Drive
Boston, MA 02210
Attorneys for Plaintiff REGENXBIO Inc.

VIA ELECTRONIC MAIL

Amy M. Dudash, Esquire
MORGAN, LEWIS & BOCKIUS LLP
1201 North Market Street, Suite 2201
Wilmington, DE 19801
*Attorneys for Plaintiff The Trustees of the University
of Pennsylvania*

VIA ELECTRONIC MAIL

Eric Kraeutler, Esquire
Julie S. Goldemberg, Esquire
MORGAN, LEWIS & BOCKIUS LLP
1701 Market Street
Philadelphia, PA 19103-2921
*Attorneys for Plaintiff The Trustees of the University
of Pennsylvania*

VIA ELECTRONIC MAIL

Janice H. Logan, Esquire
MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Avenue, NW
Washington, DC 20004
*Attorneys for Plaintiff The Trustees of the University
of Pennsylvania*

VIA ELECTRONIC MAIL

/s/ Derek J. Fahnestock

Derek J. Fahnestock (#4705)